Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review
Burrows GD, Maguire KP, Norman TR
Department of Psychiatry,
University of Melbourne,
Heidelberg, Victoria, Australia.
J Clin Psychiatry 1998; 59 Suppl 14:4-7
- ABSTRACT
Reboxetine is a unique selective
norepinephrine reuptake inhibitor (NRI) with proven antidepressant efficacy
in pharmacologic and biochemical tests predictive of antidepressant
properties. Comprehensive clinical trials, including 8 placebo-controlled
and/or active treatment-controlled studies, plus 4 open studies, have
assessed the short-term and long-term efficacy and tolerability of
reboxetine in patients with major depressive disorders and dysthymia. Results from a total of 690 patients who entered 5 open or
placebo-controlled studies are summarized in this paper. Four hundred
forty-nine patients with a diagnosis of either major depressive disorder or
dysthymia were treated with reboxetine in these clinical studies of 4 weeks'
to 12 months' duration. In a 6-week placebo-controlled study, clinically
significant improvement (> or = 50% reduction in Hamilton Rating Scale
for Depression total score) was observed at last assessment in 74% of
reboxetine-treated patients compared with 20% of patients in the placebo
group. Similar results were observed in the 6-week run-in phases of the 3
long-term studies, where the efficacy of reboxetine was maintained over the
12-month study period. Reboxetine was well tolerated; adverse events
reported were mainly mild to moderate in severity, and there were no
clinically significant changes in vital signs or laboratory parameters. The
first in its class, reboxetine, a selective NRI, will provide a valuable
addition to the existing armamentarium of agents used in the treatment of
depression.
Reboxetine research /
abstracts
1. Reboxetine
role in antidepressant therapy
2. Reboxetine
efficacy and tolerability
3. Reboxetine
clinical
pharmacologic profile
4. Reboxetine Inhibiting
noradrenaline and serotonin reuptake
5. Reboxetine
and depression in the elderly
6. Reboxetine
with severe major depressive disorder
7. Reboxetine
clinical efficacy in major depression
8. Reboxetine
tolerability
and safety for major depression
9. Reboxetine
comparison with fluoxetine
10. Reboxetine
versus fluoxetine, impact on social functioning
11. Reboxetine versus
fluoxetine, differential effects
12. Reboxetine
prevents relapse in major depression
13. Reboxetine
efficacy compared with imipramine
14. Noradrenaline
reuptake inhibition
15. Antidepressants
noradrenergic versus serotonergic
16. Reboxetine
in the treatment of bulimia
17. Reboxetine
hemodynamic
effects in healthy males
18. Reboxetine
effects of antidepressant therapy
19. Reboxetine
place in antidepressant therapy
20. Reboxetine
stimulant effects in patients with narcolepsy
21. Reboxetine
selective noradrenaline reuptake inhibitor (NARI)
Reboxetine
manufacturer's product insert
-
